{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/fungal-skin-infection-scalp/prescribing-information/oral-itraconazole/","result":{"pageContext":{"chapter":{"id":"599d0b59-095a-52c5-8bd1-289c5e9c48af","slug":"oral-itraconazole","fullItemName":"Oral itraconazole","depth":2,"htmlHeader":"<!-- begin field 83cdbd59-67d4-419f-b365-a8c5015ad488 --><h2>Oral itraconazole</h2><!-- end field 83cdbd59-67d4-419f-b365-a8c5015ad488 -->","summary":"","htmlStringContent":"<!-- begin item 6a70e986-e7c2-4dff-b581-a8c5015ad3a1 --><!-- end item 6a70e986-e7c2-4dff-b581-a8c5015ad3a1 -->","topic":{"id":"2366ecbc-4749-5ca6-8bc3-3873089df3da","topicId":"0fd8e2d0-69ae-41e6-b283-543453f673bc","topicName":"Fungal skin infection - scalp","slug":"fungal-skin-infection-scalp","lastRevised":"Last revised in April 2018","chapters":[{"id":"8a51d4c9-69eb-58f9-ac0b-38f666f1f848","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"97441633-de03-58fd-9e1b-bb42c2828337","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7bc5a70d-2277-5bff-9951-bb0c0ab337ef","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f9145ac8-339e-59bb-b8ad-25b709acdacb","slug":"changes","fullItemName":"Changes"},{"id":"d0c182d2-7ce4-57e0-9dee-362b0b530365","slug":"update","fullItemName":"Update"}]},{"id":"6f048cdd-1cbb-5611-a5e0-8361b221db8a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"599dbe6a-d7a3-5f91-91ed-4be709b1180c","slug":"goals","fullItemName":"Goals"},{"id":"84c3bfe1-6c40-57e4-a749-77a9946a89e3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ac49d0bf-50dc-5071-a82b-62723de01de5","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"60065f70-8af3-5f60-9dca-ff069607e2bc","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"fba31ad2-44ba-5fe6-bf46-7345ab044a0e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d12ccb71-eddd-5517-8749-1217ba0b4eb6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ba0c5ffb-2309-5d72-90e0-4c09ec2762ad","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a7a6e00a-8e02-5305-be1d-1aa4389187a5","slug":"definition","fullItemName":"Definition"},{"id":"a7f24440-b63f-56f4-8c94-3bb4b1877412","slug":"prevalence","fullItemName":"Prevalence"},{"id":"015c5679-e685-58cd-b557-2ed3559a9603","slug":"complications","fullItemName":"Complications"},{"id":"8fa3f79d-ba1c-5733-8306-100d8afeabfb","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"fa2925a0-ec3e-5255-b9f9-7959141a2e82","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b464e67b-56da-51d3-a0d4-4577dd9c24f7","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"4d8408bc-15aa-5151-a55a-b7849dcb8387","slug":"assessment","fullItemName":"Assessment"},{"id":"67ef57a0-32a1-5271-8ef9-7a7e9e1e5a24","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"05c0fb7d-20c2-5b68-9935-1d3c3f46f68d","fullItemName":"Management","slug":"management","subChapters":[{"id":"263ea5e0-37c2-539f-8fd6-e1218c2c16a1","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"2c583161-dd9d-5bf1-9fb1-a1395842cac9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"b923eed5-33a1-596e-974f-5611050a47c7","slug":"oral-terbinafine","fullItemName":"Oral terbinafine"},{"id":"eb8ea077-2ef7-5dd1-b454-43ca5a07d5a0","slug":"oral-griseofulvin","fullItemName":"Oral griseofulvin"},{"id":"599d0b59-095a-52c5-8bd1-289c5e9c48af","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"e6d4f0f1-7501-5b3f-9954-957d8152ffb7","slug":"topical-antifungals","fullItemName":"Topical antifungals"}]},{"id":"cc03af24-7789-56ce-978f-b905a9611cb5","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ce8e8c93-7919-5160-9ad5-965fcd16658f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"e05609c9-c42a-5eec-b055-39a296c3e2ea","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e4f27b22-bcda-54f2-83f3-4ebf35f962ba","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0ce2862f-cdca-57b0-9998-9bc40799914a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"7e057656-6867-5510-95c7-019671326f4b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"687c951d-457b-52b6-93f8-e38d5eafe6ed","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f17589e6-56a0-535c-aa03-0856855943bb","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2c583161-dd9d-5bf1-9fb1-a1395842cac9","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"f38ea75e-f0d5-5653-84f4-756707d28b75","slug":"dosing-schedule","fullItemName":"Dosing schedule","depth":3,"htmlHeader":"<!-- begin field 31dcccec-78fb-4031-9edc-a8c5015aeeca --><h3>Dosing schedule</h3><!-- end field 31dcccec-78fb-4031-9edc-a8c5015aeeca -->","summary":"","htmlStringContent":"<!-- begin item b0d6256b-f024-4bbc-ab10-a8c5015aee3c --><!-- begin field 9950372d-36be-4da5-a118-a8c5015aeeca --><p><strong>Itraconazole is not licensed for the treatment of fungal scalp infection in the UK. Adult doses have been extrapolated from treatment doses for tinea pedis.</strong></p><ul><li>For children aged 1–17 years, prescribe 3–5 mg/kg once daily (maximum per dose 200 mg) for 4 weeks.</li><li>For adults, prescribe 100 mg daily for 4 weeks.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Fuller, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">BNF 75, 2018</a>] </p><!-- end field 9950372d-36be-4da5-a118-a8c5015aeeca --><!-- end item b0d6256b-f024-4bbc-ab10-a8c5015aee3c -->","subChapters":[]},{"id":"2c6dc901-0f8a-51f4-b21f-b5e051149edd","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field b35d498f-6634-45df-98ab-a8c5015b0245 --><h3>Contraindications and cautions</h3><!-- end field b35d498f-6634-45df-98ab-a8c5015b0245 -->","summary":"","htmlStringContent":"<!-- begin item f61086d7-fe24-47ef-b98a-a8c5015b01b4 --><!-- begin field 9071dda3-9c2a-4f02-a848-a8c5015b0245 --><p><strong>Do not prescribe itraconazole to people with:</strong></p><ul><li>Acute porphyria.</li><li>Ventricular dysfunction or a history of heart failure — itraconazole has been shown to have a negative inotropic effect.</li></ul><p><strong>Prescribe itraconazole with caution in people:</strong></p><ul><li>At high risk of heart failure, including people on treatment with negative inotropic drugs (such as calcium-channel blockers).</li><li>Who are immunocompromised (for example people with AIDS, on chemotherapy, have neutropenia, or previous organ transplants).</li><li>With acute liver disease, or a history of hepatotoxicity with other drugs — consider monitoring liver function tests (LFTs). Advise immediate LFTs if symptoms of possible liver toxicity develop, such as anorexia, nausea, vomiting, fatigue, abdominal pain, or dark urine.</li><li>With renal impairment.</li><li>Taking drugs such as astemizole, pimozide, quinidine, or terfenadine that may prolong the QT interval, as there is a risk of cardiac arrhythmias.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">BNF 75, 2018</a>] </p><!-- end field 9071dda3-9c2a-4f02-a848-a8c5015b0245 --><!-- end item f61086d7-fe24-47ef-b98a-a8c5015b01b4 -->","subChapters":[]},{"id":"e6ac43ef-26a7-5bd4-97bc-1014e0dacf0b","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 6dac9adb-725b-4e85-be00-a8c5015b13cc --><h3>Adverse effects</h3><!-- end field 6dac9adb-725b-4e85-be00-a8c5015b13cc -->","summary":"","htmlStringContent":"<!-- begin item cc711416-f3ac-456d-adee-a8c5015b133b --><!-- begin field 22c45833-a989-4bfa-a383-a8c5015b13cc --><p><strong>Adverse effects of itraconazole include:</strong></p><ul><li>Gastrointestinal — nausea, abdominal pain (common); vomiting, diarrhoea, constipation, dyspepsia, taste disturbance, flatulence (uncommon). Rarely pancreatitis.</li><li>Hepatobiliary — hyperbilirubinaemia (uncommon). Rarely hepatotoxicity (including acute liver failure).</li><li>Nervous system — headache, dizziness, paraesthesia (uncommon).</li><li>Skin and subcutaneous tissue — rash (common); alopecia, urticaria, pruritus (uncommon).</li><li>Other — arthralgia, myalgia, heart failure, erectile dysfunction, menstrual disorders, oedema, tinnitus, visual disturbance.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">BNF 75, 2018</a>] </p><!-- end field 22c45833-a989-4bfa-a383-a8c5015b13cc --><!-- end item cc711416-f3ac-456d-adee-a8c5015b133b -->","subChapters":[]},{"id":"e5ae62ff-3261-5457-a409-db59e3eba2c1","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field b19d711f-e81d-4283-8cb6-a8c5015b279c --><h3>Drug interactions</h3><!-- end field b19d711f-e81d-4283-8cb6-a8c5015b279c -->","summary":"","htmlStringContent":"<!-- begin item 0e122b22-3d6d-4fcf-b947-a8c5015b26f0 --><!-- begin field b773e750-accf-46f8-84eb-a8c5015b279c --><p><strong>Itraconazole is metabolized by the cytochrome p450 3A4 (isoenzyme CYP34A) and it interacts with a number of liver enzyme-inducing and liver enzyme-inhibiting drugs.</strong></p><ul><li>Itraconazole levels may be reduced by the following drugs:<ul><li>Carbamazepine, phenobarbital, phenytoin — monitor itraconazole efficacy and increase dose if necessary.</li><li>Rifampicin, rifabutin — monitor itraconazole efficacy and increase dose if necessary.</li><li>St John’s wort — avoid concurrent use.</li></ul></li><li>Itraconazole levels may be increased by the following drugs:<ul><li>HIV protease inhibitors (ritonavir, indinavir) — monitor for adverse effects.</li><li>Clarithromycin and erythromycin — monitor for adverse effects.</li></ul></li><li>Itraconazole may increase levels of the following drugs:<ul><li>Aliskiren — monitor for adverse effects.</li><li>Aripiprazole, quetiapine, risperidone — dose reductions may be necessary.</li><li>Quetiapine — concurrent use with itraconazole is contraindicated. If considered necessary, monitor for adverse effects and adjust dose.</li><li>Phospodiesterase-5 inhibitors (avanafil, sildenafil, vardenafil) — avoid concurrent use with avanafil; reduce dose of sildenafil or vardenafil.</li><li>Benzodiazepines (alprazolam, triazolam, midazolam) — dose reductions may be required.</li><li>Calcium-channel blockers (amlodipine, verapamil) — monitor for adverse effects.</li><li>Colchicine — dose adjustment may be necessary.</li><li>Corticosteroids (budesonide, dexamethasone) — avoid concurrent use.</li><li>Digoxin — monitor the effects of digoxin; digoxin dose may need to be reduced by 50–75%.</li><li>Disopyramide — avoid concurrent use.</li><li>Domperidone — possible increased risk of ventricular arrhythmias. Avoid concurrent use.</li><li>Eplerenone — concurrent use is contraindicated.</li><li>Ergot alkaloids (such as ergotamine and ergometrine) — increased risk of ergotism. Concurrent use is contraindicated.</li><li>Ivabradine — concurrent use is contraindicated.</li><li>Mizolastine — monitor for adverse effects.</li><li>Oral anticoagulants (warfarin, apixaban, dabigatran). Monitor for adverse effects and adjust doses if required.</li><li>Pimozide — increased risk of QT interval prolongation. Concurrent use is contraindicated.</li><li>Quinidine — increased risk of torsades de pointes. Concurrent use is contraindicated, but if considered necessary, monitor for adverse effects and reduce dose if required.</li><li>Ranolazine — increased risk of QT interval prolongation. Concurrent use is contraindicated.</li><li>Reboxetine — monitor for adverse effects and adjust dose if required.</li><li>Solifenacin — restrict dose of solifenacin to 5 mg daily.</li><li>Statins (lovastatin, simvastatin) — avoid concurrent use.</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">BNF 75, 2018</a>] </p><!-- end field b773e750-accf-46f8-84eb-a8c5015b279c --><!-- end item 0e122b22-3d6d-4fcf-b947-a8c5015b26f0 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}